Project Grant HT94252410908
Award Date
10/1/24
Completion Date
9/30/27
Dollars Obligated
$556K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Omaha, NE 68198, USA
Similar Awards
This $602,550 Project Grant award from the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420) supports adoptive cellular therapy research for pancreatic cancer. The awardee, the University of Nebraska Medical Center (UNMC), will conduct innovative biomedical research to develop novel therapeutic approaches, perform clinical trials, and provide technical expertise in this critical medical field. As a prominent academic research...
The Defense Health Agency awarded a $602,814 Project Grant to the University of Nebraska Medical Center (UNMC) under the Military Medical Research and Development program (CFDA 12.420). The grant, with a performance period from November 1, 2024 to October 31, 2027, supports research to investigate "Targeting Extracellular Nucleoside Metabolism as a Strategy to Potentiate the Effects of Immunotherapy in Pancreatic Ductal Adenocarcinoma." The project aims to explore innovative approaches...
The Department of the Army Medical Command awarded a $1.5 million Project Grant to the University of Nebraska Medical Center to support research targeting nuclear importins in pancreatic ductal adenocarcinoma (PDAC) under the Military Medical Research and Development program. The three-year award beginning July 1, 2022 will fund research exploring medical solutions for pancreatic cancer through investigation of nuclear transport proteins that mediate entry of molecules into the cell nucleus....
This $183,220 Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) is supporting research at the University of Nebraska Medical Center (UNMC) to target the CCL17/CCR4 axis in order to eradicate lung cancer brain metastasis. The award commenced on February 1, 2025 and is scheduled for completion by January 31, 2026. UNMC, a prominent academic research institution, is leveraging its expertise in biomedical...
The University of Nebraska Medical Center (UNMC) was awarded a $1,544,999.00 Project Grant by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to conduct research on a "NOVEL ER STRESS MITIGATION PATHWAY IN ERBB2-DRIVEN ONCOGENESIS". The grant, which has a performance period from May 1, 2024 to April 30, 2027, will support UNMC's investigation of an innovative pathway for mitigating endoplasmic reticulum (ER) stress in ErbB2-driven...
The Defense Health Agency awarded a $579,375 Project Grant to the University of Nebraska Medical Center through the Military Medical Research and Development program (CFDA 12.420) to support research targeting APE1 interaction with DNA G-quadruplex to prevent metastasis in triple-negative breast cancer. The three-year award beginning December 30, 2022 will fund research by the University of Nebraska Medical Center to investigate medical solutions for metastatic breast cancer through innovative...
The Defense Health Agency awarded a $579,375 Project Grant to the University of Nebraska Medical Center to support research targeting APE1 interaction with DNA G-quadruplex to prevent metastasis in triple-negative breast cancer. The grant is funded through the Military Medical Research and Development program (CFDA 12.420) and aims to transform health care for service members and the public through innovative biomedical research investigating medical solutions for the battlefield. The University...
The University of Nebraska Medical Center (UNMC) was awarded a $927,000 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to conduct research titled "TARGETING FGFR4 SIGNALING TO OVERCOME CHEMORESISTANCE IN OVARIAN CANCER". The grant has an award date of July 1, 2024 and an ultimate completion date of June 30, 2028. UNMC, a leading institution in health sciences education, innovative research, and patient care, will...
The Department of the Army Medical Command awarded a $776,293 Project Grant to Albert Einstein College of Medicine to control the burden of metastatic disease in pancreatic ductal adenocarcinoma. The grant was awarded on September 15, 2022 under the Military Medical Research and Development program (CFDA 12.420) and will run through September 14, 2025. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research with the goals of transforming...
Oregon Health & Science University was awarded a $506,554 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from July 2022 through July 2025 to elucidate mechanisms of rapid metastatic recurrence in pancreatic ductal adenocarcinoma. Through basic, applied, and advanced biomedical research supported by this program, the Army aims to transform military and public health care by...